Legend Biotech's in vivo CAR-T LB2501 showed 100% objective response and 83% complete response at the high dose in B-cell NHL, with no serious safety events and no lymphodepletion.
Alpha Score of 56 reflects moderate overall profile with moderate momentum, weak value, moderate quality, moderate sentiment.
Legend Biotech reported Phase 1 data for LB2501, an in vivo CD19/CD20 dual-targeting CAR-T therapy, at the EHA congress. A single infusion at the higher dose level (DL2) produced a 100% objective response rate (6 of 6 patients) and an 83.3% complete response rate in relapsed or refractory B-cell non-Hodgkin lymphoma. All responses were ongoing at data cutoff.
The trial treated 12 patients across two doses without the standard lymphodepletion step that current CAR-T products require. The drug is designed to generate CAR-T cells inside the patient after a single intravenous injection, skipping the weeks-long ex vivo manufacturing process.
"In vivo CAR-T represents a compelling frontier in cell therapy, enabling the generation of CAR-T cells directly within the patient," said Ying Huang, Ph.D., CEO of Legend Biotech. "These early data, with deep responses from a single infusion across patients, give us confidence in the path ahead."
At DL2, responses were seen across diffuse large B-cell lymphoma, mantle cell lymphoma, and follicular lymphoma. Across both dose levels the ORR was 50% and the CR rate was 41.7%. Patients had received a median of three prior lines of therapy, and 58.3% were refractory to their most recent treatment.
No dose-limiting toxicities, serious adverse events, ICANS, or deaths were reported. Infusion-related reactions occurred in 75% of patients, all Grade 1-2, with a median onset of 1.4 hours and recovery within 18.6 hours. Cytokine release syndrome occurred in 66.7% of patients, median onset at Day 11, duration 4.5 days. Four patients received tocilizumab; none required glucocorticoids.
CAR-T cells expanded in 100% of patients at DL2 and 83% at DL1. Cells remained detectable in peripheral blood for up to 116 days. Viral copy number peaked immediately after infusion and fell to undetectable within 24 hours. No non-specific transduction was found in NK cells or other non-T populations. Vector integrations were polyclonal and diverse, supporting proof-of-concept for in vivo T-cell engineering.
Lei Fan, M.D., Ph.D., a professor at Jiangsu Province Hospital who consulted for Legend Biotech, said: "The responses observed at the higher dose level achieved a 100% objective response rate, together with a favorable safety profile and the absence of lymphodepletion, support further investigation of LB2501."
Legend Biotech is best known for CARVYKTI, its approved CAR-T for multiple myeloma, developed and marketed with Johnson & Johnson. LB2501 represents a potential next step: an all-in-one therapy that could be administered in a single clinic visit without external manufacturing. If later-stage data hold, the product would compete in a large addressable market – B-cell NHL accounts for roughly 85% of non-Hodgkin lymphoma cases.
The Phase 1 study is still enrolling at higher dose levels. The next data readout will show whether durability and response rates improve further or whether off-target effects emerge at higher doses. For now, the 100% ORR at DL2 provides the first clinical evidence that in vivo CAR-T can match the efficacy of traditional CAR-T without the logistical burden.
Prepared with AlphaScala research tooling and grounded in primary market data: live prices, fundamentals, SEC filings, hedge-fund holdings, and insider activity. Each story is checked against AlphaScala publishing rules before release. Educational coverage, not personalized advice.